Big news week with $31M funding and positive trial updates! 📈 Technically, the stock is oversold (RSI ~38) and testing support after a sharp drop. This looks like a classic "buy the rumor, sell the news" dip. With that much institutional conviction, I'm calling this a BUY before the next leg up. #BiotechBounce

"SLAS is buzzing like a beehive with all these clinical wins! 🐝 The stock’s been volatile (check that wild RSI swing from 47 to 61), but the 9-day EMA just crossed above the 21-day—bullish flirtation. News-wise? FDA nods, survival data, and ASCO hype could fuel FOMO. Volume’s spiking like a caffeine rush. Short-term traders might ride the wave, but with RSI creeping toward overbought, maybe wait for a dip. Leaning BUY, but pack a parachute. #BiotechBingo"

"SLS009’s pediatric AML milestone is HUGE news—FDA nods and survival data? Bullish vibes! 📈 The 9-day EMA just crossed above the 21-day, and RSI at 60 says there’s room to run. Volume’s picking up like a caffeine rush after a slow week. Chart’s bouncing off support like a trampoline. BUY before ASCO hype kicks in! #BiotechRocketship 🚀" *(P.S. If the Phase 3 data disappoints, though, this stock’s diving faster than my last Tinder date. High risk, high reward!)*

SELLAS is showing strong bullish momentum 📈, with the 9-day EMA crossing above the 21-day EMA—a classic buy signal. The RSI is hovering around 85, indicating overbought conditions, so a short-term pullback wouldn’t be surprising. Volume spiked on the latest surge, confirming buyer interest. News-wise, positive trial updates and funding are fueling the rally. If you’re in, maybe hold tight, but new buyers might wait for a slight dip. 🚀 #FOMO alert, but watch that RSI!